Conversion of a potent platelet activating factor antagonist to N-(acyloxyalkyl)pyridinium salts successfully improved aqueous solubility for intravenous administration, leading to the clinical evaluation of ABT-299 for sepsis.
Answers are grounded in this paper and cite their sources.
May enable IV prodrug delivery of PAF antagonists; leaves open clinical translation in sepsis.
Pyrrolothiazole 4 is a potent antagonist of platelet activating factor-mediated effects in a variety of in vitro and in vivo assays. Despite its positive activity in models of inflammation and septic shock, 4 lacks the aqueous solubility necessary for intravenous administration. This deficit was overcome by conversion of 4 to water-soluble pyridinium prodrugs. A two-step procedure was used to prepare a series of N-(acyloxyalkyl)pyridinium salts, all of which exhibited aqueous solubility of greater than 20 mg/mL. The rate of conversion of these prodrugs to 4 was faster in human plasma than in pH 7 aqueous buffer. This rate difference was shown to be due to serum enzymes since the conversion in plasma was significantly slower in the presence of a serine esterase inhibitor. A strong correlation between prodrug structure and buffer/plasma half-life was established. The N-(acetyloxymethyl)pyridinium prodrug 11 (ABT-299) is currently undergoing clinical evaluation for the treatment of sepsis.
No takes yet. Share an insight, caveat, or question.
Davidsen et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: